SGLT-2 Inhibitor: Difference between revisions
ClaireLewis (talk | contribs) |
Elcatracho (talk | contribs) (→Common) |
||
| Line 12: | Line 12: | ||
===Common=== | ===Common=== | ||
*[[UTI]] | *[[UTI]] | ||
*Genital candidiasis | *Genital [[candidiasis]] | ||
*Weight loss | *Weight loss | ||
*Dehydration/Orthostasis | *Dehydration/Orthostasis | ||
Revision as of 03:10, 8 March 2021
Administration
- Type: Oral Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule